What happened
Jiexin Medical Technology (Ningbo) Co., Ltd. has completed an Angel+ financing round of tens of millions of yuan, led by Chengtou Investment, with participation from Sanjiang Capital and Qianrong Holdings, and continued support from existing shareholder Daoyuan Capital.
The funds will be used primarily for factory construction, market promotion, and new product development.
The company, founded in 2024 and based in Cixi, Ningbo, Zhejiang, focuses on cardiac electrophysiology and other cardiovascular interventional markets, offering innovative surgical solutions for interventional physicians and patients.
Why it matters
This funding round highlights growing investor interest in the cardiac electrophysiology interventional device sector, as companies accelerate commercialization and listing efforts.
Jiexin Medical's products, including a room-septum puncture system and a balloon mapping catheter, have received national medical device registration certificates, positioning the company to expand from access-device tools to specific electrophysiology procedure consumables.
The company's recent acquisition of a national medical insurance consumables classification code for its balloon mapping catheter signals progress toward market adoption and reimbursement.
Key facts
Jiexin Medical completed an Angel+ financing round of tens of millions of yuan.
The round was led by Chengtou Investment, with Sanjiang Capital and Qianrong Holdings as followers, and Daoyuan Capital as an existing shareholder.
The company was established in 2024 and is headquartered in Cixi, Ningbo, Zhejiang.
Its room-septum puncture system and balloon mapping catheter have received registration certificates from the National Medical Products Administration.
The balloon mapping catheter recently obtained a national medical insurance consumables classification code.
What to watch next
How Jiexin Medical utilizes the new funds to scale up manufacturing and expand market reach for its approved products.
Whether the company can leverage its product innovations to capture a larger share of the cardiac electrophysiology interventional market, given increasing competition and capital activity in the sector.
Potential future funding rounds or strategic partnerships as the company advances its pipeline and commercial operations.